A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
Clinical trial NCT07269782 · RECRUITING
Trial details
- NCT number
- NCT07269782
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-01-20
- Primary completion
- 2026-07-10
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.